Literature DB >> 12775634

Shared scheme for assessing drugs for multiple sclerosis: why are eyes tightly shut to considering causes other than autoimmunity?

Abhijit Chaudhuri, Peter O Behan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12775634      PMCID： PMC1126068          DOI： 10.1136/bmj.326.7400.1213

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  3 in total

1.  Effective clinical innovation: an ethical imperative.

Authors:  David F Horrobin
Journal:  Lancet       Date:  2002-05-25       Impact factor: 79.321

2.  Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis.

Authors:  Cathie L M Sudlow; Carl E Counsell
Journal:  BMJ       Date:  2003-02-15

3.  Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis.

Authors:  M Filippi; M Bozzali; M Rovaris; O Gonen; C Kesavadas; A Ghezzi; V Martinelli; R I Grossman; G Scotti; G Comi; A Falini
Journal:  Brain       Date:  2003-02       Impact factor: 13.501
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.